Log in to search using one of your social media accounts:


Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.

Conclusion Alpelisib demonstrated a tolerable safety profile and encouraging preliminary activity in patients with PIK3CA-altered solid tumors, supporting the rationale for selective PI3Kα inhibition in combination with other agents for the treatment of PIK3CA-mutant tumors. PMID: 29401002 [PubMed - as supplied by publisher]
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: J Clin Oncol Source Type: research

Related Links:

More News: Breast Cancer | Cancer | Cancer & Oncology | Cervical Cancer | Colon Cancer | Colorectal Cancer | Endometrial Cancer | Genetics | Oral Cancer | Rectal Cancers | Study | Toxicology